Tags

Type your tag names separated by a space and hit enter

Ingrown toenail relief drug products for over-the-counter human use. Final rule.
Fed Regist. 2003 May 07; 68(88):24347-9.FR

Abstract

The Food and Drug Administration (FDA) is issuing a final rule establishing conditions under which over-the-counter (OTC) ingrown toenail relief drug products containing sodium sulfide 1 percent in a gel vehicle are generally recognized as safe and effective and not misbranded. This rule also amends the regulation that lists nonmonograph active ingredients in OTC drug products for ingrown toenail relief by removing sodium sulfide from that list. This final rule is part of FDA's ongoing review of OTC drug products.

Authors

Food and Drug Administration, HHS
No affiliation info available

MeSH

HumansNails, IngrownNonprescription DrugsProduct LabelingSulfidesUnited StatesUnited States Food and Drug Administration

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12737160

Citation

Food and Drug Administration, HHS. "Ingrown Toenail Relief Drug Products for Over-the-counter Human Use. Final Rule." Federal Register, vol. 68, no. 88, 2003, pp. 24347-9.
Food and Drug Administration, HHS. Ingrown toenail relief drug products for over-the-counter human use. Final rule. Fed Regist. 2003;68(88):24347-9.
Food and Drug Administration, HHS. (2003). Ingrown toenail relief drug products for over-the-counter human use. Final rule. Federal Register, 68(88), 24347-9.
Food and Drug Administration, HHS. Ingrown Toenail Relief Drug Products for Over-the-counter Human Use. Final Rule. Fed Regist. 2003 May 7;68(88):24347-9. PubMed PMID: 12737160.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ingrown toenail relief drug products for over-the-counter human use. Final rule. A1 - ,, PY - 2003/5/10/pubmed PY - 2003/5/17/medline PY - 2003/5/10/entrez SP - 24347 EP - 9 JF - Federal register JO - Fed Regist VL - 68 IS - 88 N2 - The Food and Drug Administration (FDA) is issuing a final rule establishing conditions under which over-the-counter (OTC) ingrown toenail relief drug products containing sodium sulfide 1 percent in a gel vehicle are generally recognized as safe and effective and not misbranded. This rule also amends the regulation that lists nonmonograph active ingredients in OTC drug products for ingrown toenail relief by removing sodium sulfide from that list. This final rule is part of FDA's ongoing review of OTC drug products. SN - 0097-6326 UR - https://www.unboundmedicine.com/medline/citation/12737160/Ingrown_toenail_relief_drug_products_for_over_the_counter_human_use__Final_rule_ DB - PRIME DP - Unbound Medicine ER -